Health Care • Medical/Dental Instruments
$24.31 ▲ +0.40
(+1.67%)
MKT CAP: $550.7M • VOL: 157.9K
52W L $15 52W H $38
TCMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $329.5M | $293.0M | $274.4M |
| YoY Revenue Growth % | +12.5% | +6.8% | — |
| Gross Profit | $250.1M | $216.7M | — |
| Gross Margin % | 75.9% | 74.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $29.3M | $22.2M | $18.0M |
| Operating Margin % | 8.9% | 7.6% | 6.6% |
| Net Income (GAAP) | $19.1M | $17.0M | $28.5M |
| EBITDA (Normalized) | $31.2M | $24.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $42.8M | $40.7M | $35.9M |
| Capital Expenditures (CapEx) | $2.4M | $2.4M | — |
| Free Cash Flow (FCF) | $40.4M | $38.3M | $35.9M |
| FCF Margin % | 12.3% | 13.1% | 13.1% |
| Return on Invested Capital (ROIC %) | 17.1% | 14.3% | — |
| Cash & Short-Term Equivalents | $83.4M | $94.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $218.9M | $216.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TCMD.